<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333069</url>
  </required_header>
  <id_info>
    <org_study_id>cat in uveitic patients</org_study_id>
    <nct_id>NCT04333069</nct_id>
  </id_info>
  <brief_title>Outcome of Cataract Surgery With Uveitis</brief_title>
  <official_title>Outcome of Cataract Surgery in Patient With Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate outcome of cataract surgery in different types of uveitis as
      regarding best corrected visual acuity (BCVA) and rate of post operative complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataract is the main cause of reversible blindness in patients with uveitis. Cataract occurs
      in up to 50% to 70% of patients with uveitis.

      Preoperative complications, including anterior synechiae, posterior synechiae, and pupillary
      membrane formation, may increase surgical challenges. In addition, recurrent inflammation
      increases the incidence of postoperative complications and often affects the visual
      prognosis. In recent years, phacoemulsification with intra ocular lens (IOL)implantation has
      become the main surgical method for treating uveitis (complicated cataract), and the visual
      prognosis of patients who undergo this procedure is usually favorable.

      Surgical treatment may be effective but is associated with higher rates of complication than
      in non uveitic eyes. Cystoid macular edema (CME) is the most common complication cataract
      surgery in the general population. Although, in most cases, the macular edema is
      self-limited, in rare cases it can lead to long-term visual deterioration that is difficult
      to treat.

      Another common complication after cataract surgery is posterior capsule opacification (PCO) ,
      leading to symptoms of glare or blurred vision, reduced visual acuity, or impaired posterior
      segment exam. Factors that are critical in the development of PCO include surgical technique,
      type of implanted intra ocular lens (IOL) either foldable hydrophilic acrylic, hydrophobic
      acrylic or silicone and postoperative control of uveitis
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>final postoperative uncorrected visual acuity (UCVA)</measure>
    <time_frame>1 week post operative</time_frame>
    <description>post operative uncorrected visual acuity which mean visual acuity without spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>final postoperative uncorrected visual acuity (UCVA)</measure>
    <time_frame>1month post operative</time_frame>
    <description>post operative uncorrected visual acuity which mean visual acuity without spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>final postoperative uncorrected visual acuity (UCVA)</measure>
    <time_frame>3months post operative</time_frame>
    <description>post operative uncorrected visual acuity which mean visual acuity without spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>final postoperative uncorrected visual acuity (UCVA)</measure>
    <time_frame>6months post operative</time_frame>
    <description>post operative uncorrected visual acuity which mean visual acuity without spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final post operative best corrected visual acuity (BCVA)</measure>
    <time_frame>1 week post operative</time_frame>
    <description>Post operative visual acuity with spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final post operative best corrected visual acuity (BCVA)</measure>
    <time_frame>1month post operative</time_frame>
    <description>Post operative visual acuity with spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final post operative best corrected visual acuity (BCVA)</measure>
    <time_frame>3months post operative</time_frame>
    <description>Post operative visual acuity with spectacle correction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final post operative best corrected visual acuity (BCVA)</measure>
    <time_frame>6months post operative</time_frame>
    <description>Post operative visual acuity with spectacle correction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative complications</measure>
    <time_frame>6 months post operative</time_frame>
    <description>cystoid macular edema which mean inflammation, swelling and collection of fluid inside macula) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactivation of intraocular inflammation</measure>
    <time_frame>6 months post operative</time_frame>
    <description>Appearance of inflammatory activity inside the eye after period of quiescence of at least 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cataract; Complicata</condition>
  <arm_group>
    <arm_group_label>Uncorrected and best corrected visual acuity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cataract surgery</intervention_name>
    <description>cataract surgery in form of phaco emulsification or irrigation aspiration</description>
    <arm_group_label>Uncorrected and best corrected visual acuity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Visually significant cataract ( means opacification of the crystalline lens adequate to
        interfere with vision)in patients with uveitis controlled for at least 1month.

        Exclusion Criteria:

          -  Irreversible pathology affecting outcome e.g. macular scar ,optic atrophy, and retinal
             detachment.

          -  Patients with active uveitis (means inflammation inside the eye).

          -  Patients less than 16 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Khalaf Al Husseini, professor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wael Mohammed Ahmed Soliman, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mona Abdallah Abd AlRazik Ahmed, MD</last_name>
    <phone>01014398129</phone>
    <email>monaabdallah51290@aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Gamal Saleh, lecturer</last_name>
    <phone>01004530716</phone>
    <email>mgsaleh05@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Carpentier SJ, Jung JL, Patnaik JL, Pecen PE, Palestine AG. A Cross-Sectional Online Survey Identifies Subspecialty Differences in the Management of Pediatric Cataracts Associated with Uveitis. Ophthalmol Ther. 2020 Jun;9(2):293-303. doi: 10.1007/s40123-020-00245-x. Epub 2020 Mar 10.</citation>
    <PMID>32157612</PMID>
  </reference>
  <reference>
    <citation>Chen JL, Bhat P, Lobo-Chan AM. Perioperative Management of Uveitic Cataracts. Adv Ophthalmol Optom. 2019 Aug;4:325-339. doi: 10.1016/j.yaoo.2019.04.014. Epub 2019 May 18.</citation>
    <PMID>31788579</PMID>
  </reference>
  <reference>
    <citation>Yangzes S, Seth NG, Singh R, Gupta PC, Jinagal J, Pandav SS, Gupta V, Gupta A, Ram J. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019 Apr;67(4):490-495. doi: 10.4103/ijo.IJO_846_18.</citation>
    <PMID>30900580</PMID>
  </reference>
  <reference>
    <citation>Jinagal J, Gupta G, Agarwal A, Aggarwal K, Akella M, Gupta V, Suri D, Gupta A, Singh S, Ram J. Safety and efficacy of dexamethasone implant along with phacoemulsification and intraocular lens implantation in children with juvenile idiopathic arthritis associated uveitis. Indian J Ophthalmol. 2019 Jan;67(1):69-74. doi: 10.4103/ijo.IJO_713_18.</citation>
    <PMID>30574896</PMID>
  </reference>
  <reference>
    <citation>El Gharbawy SA, Darwish EA, Abu Eleinen KG, Osman MH. Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes. Eur J Ophthalmol. 2019 Jul;29(4):453-457. doi: 10.1177/1120672118799626. Epub 2018 Sep 11.</citation>
    <PMID>30203671</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mona Abdallah Abdal Razik Ahmed</investigator_full_name>
    <investigator_title>Assistant lecturer at Ophthalmology departmentAssiut University Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

